Adipose Tissue Blood Flow in Aging Humans | NCT06096532

Studies
Adipose Tissue Blood Flow in Aging Humans

NCT06096532

Sponsor

Mayo Clinic

Status

Recruiting

Last Update Posted

May 1, 2026Actual

Enrollment

24Estimated

Phase

Not Applicable

Conditions

Healthy
Aging

Interventions

75 gm oral glucose load

Countries

United States

Protocol Section

Identification Module Status Module Sponsor/Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms/Interventions Module Outcomes Module Eligibility Module Contacts/Locations Module References Module IPD Sharing Statement Module

Results Section

Participant Flow Module Baseline Characteristics Module Outcome Measures Module Adverse Events Module More Info Module

Annotation Section

Annotation Module

Document Section

Large Document Module

Derived Section

Miscellaneous Info Module Condition Browse Module Intervention Browse Module

Protocol Section

Identification Module

NCT ID

Results Section

No data available

No data is available for this block.

Annotation Section

No data available

No data is available for this block.

Document Section

No data available

No data is available for this block.

Derived Section

Miscellaneous Info Module

Version Holder

ID	Type	Description	Link
UL1TR002377	U.S. NIH Grant/Contract		View source

Status Module

Record Verification Date

Jan 2026

Overall Recruitment Status or Expanded Access Status

Recruiting

Last Known Status

Not provided

Delayed Posting

Not provided

Why Stopped

Not provided

Expanded Access Info

Start Date

Feb 15, 2024Actual

Primary Completion Date

Dec 30, 2028Estimated

Completion Date

Dec 30, 2028Estimated

First Submitted Date

Sep 26, 2023

First Submission Date that Met QC Criteria

Oct 19, 2023

First Posted Date

Oct 23, 2023Actual

Results Waived

Not provided

Results First Submitted Date

Not provided

Results First Submitted that Met QC Criteria

Not provided

Results First Posted Date

Not provided

Certification/Extension (aka Delayed Results) First Submitted Date

Not provided

Certification/Extension First Submitted that Passed QC Review

Not provided

Certification/Extension First Posted Date

Not provided

Last Update Submitted Date

Apr 27, 2026

Last Update Posted Date

May 1, 2026Actual

Sponsor/Collaborators Module

Responsible Party, by Official Title

Kelli A. Lytle, Principal Investigator, Mayo ClinicPrincipal Investigator

Lead Sponsor

Mayo ClinicOTHER

Collaborators

Name	Class
National Center for Advancing Translational Sciences (NCATS)	NIH

Oversight Module

Has Data Monitoring Committee (DMC)

Is FDA Regulated Drug

Is FDA Regulated Device

Is Unapproved Device

Not provided

Pediatric Postmarket Surveillance of a Device Product

Not provided

Product Exported from US

Not provided

FDAAA801 Violation

Not provided

Description Module

Brief Summary

The goal of this basic science clinical trial is to understand whether adipose tissue blood flow changes between younger and older healthy adults.

The main question[s] it aims to answer are:

Is basal and nutrient responsive adipose tissue blood flow (ATBF) different between younger and older adults
What molecular and systemic signatures related to adipose tissue blood flow are altered between these two groups.

Participants will undergo measurements of adipose tissue blood flow using the xenon washout technique, undergo 2 abdominal subcutaneous adipose tissue biopsies, and drink a sugary drink.

Detailed Description

On Visit 1, volunteers will provide written informed consent (and urine pregnancy test for women of childbearing age), complete a Dual x-ray absorptiometry scan, baseline labs (comprehensive metabolic panel) and a cardiopulmonary exercise test. Participants will arrive fasted at 08:00, and urine pregnancy test for women of childbearing age administered and an intravenous catheter will be placed. Following 30min of supine rest, baseline venous blood samples will be collected. ATBF will be assessed on participants' left abdomen first by measurement of blood flow using 133Xenon washout method. Immediately thereafter, an abdominal adipose tissue biopsy of the left side will be performed but ≥6 cm distant from location of 133Xenon injections. Subjects will them consume 75 gm glucose; because ATBF peaks 30-60 minutes following ingestion of glucose, ATBF measures will start 30 minutes after ingestion on the contralateral side followed immediately by plasma measures and another adipose tissue biopsy. During ATBF measurements, brachial blood pressure will be assessed in two-minute intervals.

Design Module

Study Type

Interventional

Number of References to an Expanded Access Study

Not provided

Expanded Access Types

Not provided

Patient Registry

Not provided

Target Follow-Up Duration

Not provided

Phases

Not Applicable

Interventional Study Design

Allocation

Biospecimen

No data available

No data is available for this block.

Enrollment

24Estimated

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
Older Adults	Other		Other: 75 gm oral glucose load
Younger Adults	Active Comparator		Other: 75 gm oral glucose load

Interventions

Name	Type	Description	Arm Group Labels	Other Names
75 gm oral glucose load	Other	Consumption of 75 gm oral glucose load in order to test nutrient responsiveness	Older Adults Younger Adults

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Adipose tissue blood flow	blood flow will be measured in the upper body subcutaneous adipose tissue using 133 Xenon washout and reported as blood flow in ml/min/100g adipose tissue.	Baseline, pre-intervention fasting and immediately following 75 gm oral glucose load

Secondary Outcomes

Measure	Description	Time Frame
Genomic alterations	RNA-Seq from adipose tissue biopsies	Baseline, pre-intervention fasting and immediately following 75 gm oral glucose load

Other Outcomes

Not provided

Eligibility Module

Eligibility Criteria

Inclusion criteria

Within the ages of 18-35 years or 65-80 years at time of study visit
BMI between 20-25.0 kg/m2.

Exclusion criteria:

Presence of diagnosed cardiometabolic diseases (e.g., Type 2 diabetes, hypertension, Heart Failure)
Taking prescription anticoagulants
Taking prescriptions or supplements that effect adipose tissue metabolism (i.e., statins, Thiazolidinediones, niacin, atypical antipsychotics, or fish oil)
Pregnant or nursing
Inability to provide written informed consent
Smokers

Accepts Healthy Volunteers

Yes

Sex

All

Sex/Gender Based

Not provided

Sex/Gender Description

Not provided

Minimum Age

18 Years

Maximum Age

80 Years

Standard Ages

AdultOlder Adult

Study Population

Not provided

Sampling Method

Not provided

Contacts/Locations Module

Central Contacts

Not provided

Overall Officials

Name	Affiliation	Role
Kelli Lytle, PhD	Mayo Clinic	Principal Investigator

Locations

Facility	Status	City	State	ZIP	Country	Contacts
Mayo Clinic Minnesota	Recruiting	Rochester	Minnesota	55905	United States

References Module

Citations

Not provided